SGHT

Sight Sciences, Inc. (NASDAQ:SGHT) is a medical device company founded in 2010 and headquartered in Menlo Park, California. The company went public in July 2021 and specializes in developing and commercializing surgical and non-surgical technologies for treating eye diseases. Sight Sciences operates in two primary segments: surgical glaucoma treatment through its <b>OMNI Surgical System</b> and dry eye disease treatment via its <b>TearCare System</b>. The company has faced significant challenges in recent years, including regulatory changes affecting Medicare reimbursement for its glaucoma procedures and ongoing efforts to establish insurance coverage for its dry eye treatments.